It should not be a premium, as the company already trades. This will add liquidity and access to additional capital in the future where required.
I dont really know if this is required, but the leadership at Telix have been on point at every turn so I am going to defer to their judgement. Ordinarily, biotech companies that have done in the past is usually a big waste of time and shareholder's funds. I know that ResMed are listed, but then COH and CSL are not, so not an absolute requirement,
Ann: Telix Plans U.S. Registered Public Offering and Listing, page-28
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.45 |
Change
0.380(2.52%) |
Mkt cap ! $5.105B | |||
| Open | High | Low | Value | Volume |
| $15.20 | $15.50 | $15.10 | $9.708M | 632.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2378 | $15.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.45 | 5415 | 2 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.42 |
Change
0.380 ( 2.17 %) |
||||
| Open | High | Low | Volume | ||
| $15.28 | $15.50 | $15.19 | 79007 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| TLX (ASX) Chart |